Brickell Enterprise Value over EBIT Trend from 2010 to 2022

BBI
 Stock
  

USD 0.12  0.00  0.00%   

Brickell Biotech Enterprise Value over EBIT is increasing over the last several years with slightly volatile swings. Enterprise Value over EBIT is predicted to flatten to -1.24. During the period from 2010 to 2022 Brickell Biotech Enterprise Value over EBIT regressed destribution of quarterly values had mean deviationof 9.09 and mean square error of  96.82. Brickell Biotech Gross Profit is most likely to decrease significantly in the upcoming years. The last year's value of Gross Profit was reported at 404,000. The current Interest Expense is estimated to increase to about 63.7 K, while Consolidated Income is projected to decrease to (40.5 M).
  
Refresh
Check Brickell Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Brickell main balance sheet or income statement drivers, such as Direct Expenses of 1.7 M, Cost of Revenue of 7.3 M or Gross Profit of 414.6 K, as well as many exotic indicators such as PPandE Turnover of 4.69, Accounts Payable Turnover of 2.36 or Accrued Expenses Turnover of 0.54. Brickell financial statements analysis is a perfect complement when working with Brickell Biotech Valuation or Volatility modules. It can also supplement various Brickell Biotech Technical models. Continue to the analysis of Brickell Biotech Correlation against competitors.

Brickell Biotech Quarterly Enterprise Value over EBIT

0.0

Share

Brickell Enterprise Value over EBIT Breakdown

Showing smoothed Enterprise Value over EBIT of Brickell Biotech with missing and latest data points interpolated. Measures the ratio between [EV] and [EBITUSD].Brickell Biotech's Enterprise Value over EBIT historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Brickell Biotech's overall financial position and show how it may be relating to other accounts over time.
Enterprise Value over EBIT10 Years Trend
Increasing
Slightly volatile
 Enterprise Value over EBIT 
Share
      Timeline 

Brickell Enterprise Value over EBIT Regression Statistics

Arithmetic Mean(7.65)
Coefficient Of Variation(172.20)
Mean Deviation 9.09
Median(2.00)
Standard Deviation 13.17
Sample Variance 173.33
Range 36.00
R-Value 0.70
Mean Square Error 96.82
R-Squared 0.49
Significance 0.007904
Slope 2.36
Total Sum of Squares 2,080

Brickell Enterprise Value over EBIT History

2012 -8.0
2013 -2.0
2014 -4.0
2017 -1.0
2021 -1.15
2022 -1.24

Other Fundumenentals of Brickell Biotech

About Brickell Biotech Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Brickell Biotech income statement, its balance sheet, and the statement of cash flows. Brickell Biotech investors use historical funamental indicators, such as Brickell Biotech's Enterprise Value over EBIT, to determine how well the company is positioned to perform in the future. Although Brickell Biotech investors may use each financial statement separately, they are all related. The changes in Brickell Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Brickell Biotech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Brickell Biotech Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Brickell Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Enterprise Value over EBIT(1.15) (1.24) 
Enterprise Value over EBITDA(0.13) (0.13) 
Enterprise ValueM5.1 M
Tangible Asset Value29.7 M36.7 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA-39.4 M-40.4 M
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company was founded in 2009 and is headquartered in Boulder, Colorado. Brickell Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people.

Brickell Biotech Investors Sentiment

The influence of Brickell Biotech's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Brickell. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Brickell Biotech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Brickell Biotech's short interest history, or implied volatility extrapolated from Brickell Biotech options trading.

Current Sentiment - BBI

Brickell Biotech Investor Sentiment

Greater number of Macroaxis users are currently bullish on Brickell Biotech. What is your opinion about investing in Brickell Biotech? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish

Pair Trading with Brickell Biotech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Brickell Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Brickell Biotech will appreciate offsetting losses from the drop in the long position's value.

Brickell Biotech Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to Brickell Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Brickell Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Brickell Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Brickell Biotech to buy it.
The correlation of Brickell Biotech is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Brickell Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Brickell Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Brickell Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to the analysis of Brickell Biotech Correlation against competitors. Note that the Brickell Biotech information on this page should be used as a complementary analysis to other Brickell Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Complementary Tools for Brickell Stock analysis

When running Brickell Biotech price analysis, check to measure Brickell Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brickell Biotech is operating at the current time. Most of Brickell Biotech's value examination focuses on studying past and present price action to predict the probability of Brickell Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brickell Biotech's price. Additionally, you may evaluate how the addition of Brickell Biotech to your portfolios can decrease your overall portfolio volatility.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Is Brickell Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brickell Biotech. If investors know Brickell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brickell Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
14.8 M
Quarterly Revenue Growth YOY
4.41
Return On Assets
-0.85
Return On Equity
-1.76
The market value of Brickell Biotech is measured differently than its book value, which is the value of Brickell that is recorded on the company's balance sheet. Investors also form their own opinion of Brickell Biotech's value that differs from its market value or its book value, called intrinsic value, which is Brickell Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brickell Biotech's market value can be influenced by many factors that don't directly affect Brickell Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brickell Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Brickell Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brickell Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.